NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; innovative preclinical studies, including the use of new clinically-relevant models and imaging technologies, which could lead to first-in-human clinical trials, and therapeutic outcome disparities, including biomarkers or genetic/epigenetic signatures, among diverse racial/ethnic populations, including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines.

The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (pre-clinical or clinical).


  • Application Due Date(s): October 18, 2019; February 20, 2020, June 19, 2020; October 20, 2020; February 19, 2021; June 21, 2021; October 20, 2021; February 22, 2022; June 21, 2022
  • AIDS Application Due Date(s): December 18, 2019; March 20, 2020; July 20, 2020; December 18, 2020; March 19, 2021; July 20, 2021; December 17, 2021; March 21, 2022; July 20, 2022

PAR-19-356 Expiration Date July 21, 2022

Agency Website



Amount Description

The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.

Funding Type





Medical - Clinical Science
Medical - Translational

External Deadline

October 18, 2019